Application of Ozone Therapy in the Conservative Surgical Treatment of Osteonecrosis of the Jaw: Preliminary Results †
1. Objectives
2. Materials and Methods
- Antibiotic prophylaxis and one-minute mouthrinse with 0.2% Chlorhexidine from the day before and for six days after the surgical procedure.
- Local anesthesia achieved using 3% mepivacaine hydrochloride without adrenaline
- Elevation of a full-thickness mucoperiosteal flap
- Curettage of the necrotic bone
- Insufflation inside the bone defect (15 mL dosage) (by pink Venocat cannula 20Gx1.1/4″/1.10 × 32 mm) and injection around its edges (15 mL dosage) (by 26Gx½” needle—0.45 × 13 mm) of an oxygen-ozone mixture (15γ concentration)
- Tension-free suture
3. Results
4. Conclusions
Conflicts of Interest
References
- Di Fede, O.; Mauceri, R.; Panzarella, V.; Maniscalco, L.; Bedogni, A.; Licata, M.E.; Albanese, A.; Toia, F.; Cumbo, E.M.G.; Mazzola, G.; et al. Conservative Surgical Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw with Er, Cr: YSGG Laser and Platelet-Rich Plasma: A Longitudinal Study. BioMed Res. Int. 2018, 2018, 3982540. [Google Scholar] [CrossRef]
- Ripamonti, C.I.; Maniezzo, M.; Boldini, S.; Pessi, M.A.; Mariani, L.; Cislaghi, E. Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates—Preliminary data: Medical ozone gas insufflation in treating ONJ lesions. J. Bone Oncol. 2012, 1, 81–87. [Google Scholar] [CrossRef] [PubMed]
- PROMaF Protocol: Prevention and Research on Medication—Related Osteonecrosis of the Jaws, 2014. Available online: http://www.policlinico.pa.it/portal/pdf/promaf/1.%20Cosa%20è%20PROMaF%20__ad%20uso%20degli%20operatori%20sanitari.pdf (accessed on 1 December 2014).
Age (yrs) | 65.4 ± 13 |
Male | 7 (30%) |
Female | 16 (70%) |
Cancer | 17 (70%) |
Non-Cancer | 6 (30%) |
Involved bone | |
Maxilla | 6 (30%) |
Mandible | 17 (70%) |
ONJ stage * | |
I A | 4 (17%) |
I B | 5 (22%) |
II A | 4 (17%) |
II B | 7 (31%) |
III B | 3 (13%) |
ONJ-related medications | |
Bisphosphonates | 12 (53%) |
Denosumab | 7 (30%) |
Denosumab + Bevacizumab | 4 (17%) |
Time of administration of ONJ-related medications (mo) | |
Cancer | 21.3 ± 14.1 |
Non-Cancer | 152 ± 77.1 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mauceri, R.; Grigoli, A.D.; Giuliani, M.; Mascitti, M.; Gaizo, C.D.; Fede, O.D. Application of Ozone Therapy in the Conservative Surgical Treatment of Osteonecrosis of the Jaw: Preliminary Results. Proceedings 2019, 35, 22. https://doi.org/10.3390/proceedings2019035022
Mauceri R, Grigoli AD, Giuliani M, Mascitti M, Gaizo CD, Fede OD. Application of Ozone Therapy in the Conservative Surgical Treatment of Osteonecrosis of the Jaw: Preliminary Results. Proceedings. 2019; 35(1):22. https://doi.org/10.3390/proceedings2019035022
Chicago/Turabian StyleMauceri, Rodolfo, Anna Di Grigoli, Michele Giuliani, Marco Mascitti, Carmine Del Gaizo, and Olga Di Fede. 2019. "Application of Ozone Therapy in the Conservative Surgical Treatment of Osteonecrosis of the Jaw: Preliminary Results" Proceedings 35, no. 1: 22. https://doi.org/10.3390/proceedings2019035022
APA StyleMauceri, R., Grigoli, A. D., Giuliani, M., Mascitti, M., Gaizo, C. D., & Fede, O. D. (2019). Application of Ozone Therapy in the Conservative Surgical Treatment of Osteonecrosis of the Jaw: Preliminary Results. Proceedings, 35(1), 22. https://doi.org/10.3390/proceedings2019035022